Beam Therapeutics: Q3 Earnings Insights
Portfolio Pulse from Benzinga Insights
Beam Therapeutics (NASDAQ:BEAM) reported Q3 earnings, beating estimated earnings by 8.96% with an EPS of $-1.22 versus an estimate of $-1.34. Revenue was up $1.39 million from the same period last year. Last quarter, the company beat EPS estimates by $0.34, followed by a 0.53% drop in the share price the next day.
November 08, 2023 | 11:40 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Beam Therapeutics beat Q3 earnings estimates and reported increased revenue. However, past performance shows a share price drop following an earnings beat.
While Beam Therapeutics reported better than expected earnings and increased revenue, the company's share price has historically dropped following an earnings beat. This suggests that despite positive financial performance, market reactions may not be as favorable.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100